Amgenhas announced a significant investment of over $600 million to construct a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California. This new facility is designed to foster collaboration and accelerate the development of next-generation therapeutics by bringing together researchers, engineers, and scientists from various disciplines. The center will be equipped with advanced automation and digital capabilities, providing a cutting-edge environment for driving scientific excellence and advancements in biotechnology.

This investment underscores Amgen’s ongoing commitment to innovation within the U.S. Since the passage of the Tax Cuts and Jobs Act of 2017, the company has invested more than $40 billion in research and development and manufacturing, including over $5 billion in direct capital expenditures in the U.S. According to Amgen's Chairman and CEO, Robert A. Bradway, the new center will empower scientists to shape the future of scientific discovery and advance medicines that improve human health.

The construction of the new center is scheduled to begin in the third quarter of 2025 and is expected to create hundreds of new jobs in the U.S. This project is part of a series of recent major investments by Amgen, which also includes a $900 million expansion of its manufacturing facility in Central Ohio and a $1 billion investment for a second manufacturing plant in Holly Springs, North Carolina. As a leading biotechnology company, Amgen has been at the forefront of the industry for over 45 years, leveraging technology and human genetic data to develop innovative medicines for diseases such as cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases.